In Review: Montana legislators signaled a pause on new prescription drug legislation, opting to convene an informal, stakeholder-driven working group tied to SJ 33 to develop consensus recommendations before advancing committee bills. The Economic Affairs Interim Committee emphasized the risk of “repeating errors” from HB 740—now in rulemaking at the Office of the Commissioner of Securities and Insurance (CSI)—and acknowledged the limits of legislating complex drug supply-chain issues without sustained industry input. CSI offered to host and support the process, with meetings expected this spring and early summer and an explicit target to surface draft concepts by July 17, ahead of the September 10 deadline for committee bill approval. The process is explicitly supply-chain wide and reflects legislative caution about PBM-only solutions.

If you have any questions, please contact Tonia Sorrell-Neal at tsorrell-neal@pcmanet.org.